2-Year Overall Survival Results From DAZALS: A Phase 2, Randomized Controlled Trial of Dazucorilant, a Selective Glucocorticoid Receptor Modulator, in Amyotrophic Lateral Sclerosis

Presented: Network of Excellence for ALS Annual Meeting, 29 October 2026, Clearwater, FL

Presenter: Shafeeq Ladha, M.D.

Scientific journal publications or scientific congress presentations may include information regarding investigational products or uses.